chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous report as received from a healthcare worker refers to a 3 year old patient of unknown gender. The patient's concurrent conditions and medical history were not reported. On 27-JUL-205, the patient was vaccinated with an improperly stored dose of PROQUAD (Merck) (lot number K010211 and expiration date 17-JAN-2016, dose and route of administration were not provided). No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
Information has been received from a physician concerning a 61 year old female with a history of sneezing (week before) who on 21-OCT-2006 at 10:00 was vaccinated SC with a third dose of Pneumovax 23 (lot# 651400/0618F).  Two days later, the patient experienced a painful, swelling, erythematous left arm the size of a quarter in her arm.  Ten days later, the patient recovered.  No product quality complaint was involved.  Additional information is not expected.
pt recv vax 4NOV96PM in AM of 5NOV96 mom noticed redness & swelling on upper rt arm, on rt deltoid that is red, swollen & warm to touch;pt has had no fever, rash, resp problems or any systemic complaints;feeling well s/rt arm tender;
both times I got the vaccine the side effects were few days later, I experienced severe bruising on my legs and hips and chest pain and palpitations followed by tingling nerve on the sides of my head and bloated body. I've been also experiencing  stiffness on my hands and wrists.
elevated temp, h/a, aching all over, n/v 1DEC98;returned to school 3DEC98;
Post vax, the patient complained her index finger and thumb on her left hand went completely numb, preceded by tingling.
No Additional AE/PQC; the product possibly did go onto the patient's leg; This spontaneous report was received from a nurse and refers to a patient of unknown age and gender.  The patient's medical history, concurrent conditions and concomitant therapies were not reported.  On 22-MAY-2023, the patient was vaccinated with a dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) subcutaneous injection, 0.5 milliliter, administered for prophylaxis (strength, lot #, expiry date, and route of administration were not provided). They were intended to receive a dose of dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) subcutaneous injection (0.5 milliliter) (strength, lot #, expiry date not provided) but it was spilled on the floor because the patient moved. HCP did not believe any of the measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) was injected and stated that only the measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) was injected. While on the Phone with the HCP, it was mentioned that the product possibly did go onto the patient's leg (Accidental exposure while administering drug).
RhA flare to hands and knees, mid back felt like hives without redness. Took Tylenol PM and worked in side prone position for a few hours, then took normal Night time pills and another Tylenol PM around 8PM. Woke up feeling great!
This spontaneous report as received from a medical assistant refers to a 22 years old female patient without any pertinent medical history, drug reactions or allergies. On an unknown date, the patient was vaccinated with GARDASIL (dose, strength and route were not reported). Secondary therapies were not reported. There was no concomitant medication. Medical assistant reported that patient that received GARDASIL on an unspecified date had a pap smear in March 2014 and the result of her pap smear was "abnormal" and positive to HPV. Medical assistant stated that the patient had a biopsy done on 03-APR-2014 and the result showed the patient was "high risk HPV". No treatment was given for the adverse event. It was reported that the patient sought medical attention by seeing the physician. Medical assistant reports that the patient will be having a repeat pap smear in "three months from March 2014". Additional information has been requested.
This spontaneous report as received from a nurse refers to 4 patients of unknown age. On unknown dates during the past 6 months the 4 patients was vaccinated with a dose of 0.5ml PNEUMOVAX23 (lot #, expiration date unspecified) intramuscular. On unknown dates the patients developed injection site reactions of redness and swelling. All patients recovered within 4 days from the onset of symptoms. Nurse was not sure whether or not these patients received PNEUMOVAX23 in the past. The patients sought medical attention via office visit. Additional information has been requested.
Started to lose voice when talking, this comes and goes.  Sought care form an ENT 8/29/2022, COVID-19 test, negative, scope negative. No further testing performed as no results found.  ENT Proscribed prednisone to no effect.  Condition continues at time of reporting.
Developed really bad neck pain with pain in my Right arm. MRI on Right shoulder showed nothing significant. Never got better, Neck pain started and got MRI and Now have Degenerative Disk Disease, with Narrowing between Vertebra.
rapid, irregular heartbeat, vomiting, heart rate up to 200 BPM, dizziness, weakness, rapid ventricular response.  Taken by ambulance to Hospital Emergency Room.  about 7:30 a.m. November 9, 2021 Intravenous fluids and Diltiazem. admitted to hospital overnight
Muscle aches, shaking, cold, lasted from 8:30pm to 2am. No fever. Next day fever 101, took tylenol. Slept most of the day. Started feeling better later that day. Still not hungry.  No medical treatment received.
Initial information received on 06-Nov-2018 regarding an unsolicited valid non-serious case received from an other health professional. This case involves male patient of unknown age of who experienced tingling in his arm, back, neck, all left sided only, numbness, muscle pain and weakness, while he received vaccine FLUZONE. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included PREVNAR 13 for Immunization. On 12-Oct-2018, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED lot UI982AB via unknown route in the left deltoid. On an unknown date, the patient developed a non-serious tingling in his arm, back, neck, all left sided only following the administration of INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED. On an unknown date, the patient developed a non-serious numbness following the administration of INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED. On an unknown date, the patient developed a non-serious muscle pain following the administration of INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED. On an unknown date, the patient developed a non-serious weakness following the administration of INFLUENZA QUADRIVAL A-B MULTIDOSE VACCINE PRESERVED. (Other relevant tests included No lab data.) Final diagnosis was weakness, muscle pain, numbness and tingling in his arm, back, neck, all left sided only. The patient was treated with TRAMADOL. The patient outcome is reported as Unknown for muscle pain, as Unknown for weakness, as Unknown for numbness and as Unknown for tingling in his arm, back, neck, all left sided only. List of documents held by sender: none.
Heart disease; Different arterial diseases; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team, Program ID: The reporter is the patient.  A 70-year-old female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), in Sep2022 as dose 5 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose 1, Single), for COVID-19 immunization; Bnt162b2 (Dose 2, Single), for COVID-19 immunization; Bnt162b2 (Dose 3 (Booster), Single), for COVID-19 immunization; Bnt162b2 (Dose 4 (Booster), Single), for COVID-19 immunization. The following information was reported: CARDIAC DISORDER (non-serious), outcome "unknown", described as "Heart disease"; ARTERIAL DISORDER (non-serious), outcome "unknown", described as "Different arterial diseases".  Additional Information: The reporter reported she had four previous Pfizer COVID-19 vaccines and had her first bivalent booster dose was administered Sep2022. The reporter said she has different health conditions, including heart disease, and wanted to make sure she was up to date on her vaccines. She had a lot of health problems and different arterial diseases. She wanted to know when she can get the next shot.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
She had chills; Cough; This is a spontaneous report from a contactable consumer or other non-healthcare professional (Patient). A female patient of an unspecified age received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: solution for injection, Batch/Lot number: Unknown), via an unspecified route of administration on an unspecified date as dose 1, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. The consumer reported she should get her second vaccine. She said after her first covid dose, on an unknown date she had chills and cough that never went away. The clinical outcome of the events was not recovered.   No follow-up attempts are possible, information about lot/batch number cannot been obtained. No further information is expected.
The pt experienced a prolonged seizure 16 hours post vax. Temperature at time was 102.5 rectally. Right arms and legs were twitching. 2 months later the pt started having complex partial seizures and was diagnosed with medial temporal sclerosis. The pt is currently on Lamictal to control seizures.  Also diagnosed with OM, viral stomatitis, URI. Follow up information receivced 10/21/02 stated, "Brain damage, seizures, epilepsy"
The patient called two days after vaccines, and reported redness and swelling in the left arm where PNEUMOVAX was given. She advised that she does not have any change in mobility, but the area was just sore. I called to follow up with the patient today, and she advised that the area has gone down, and was a little red. She advised that she was a little sore in her elbow, but that she was fine. I advised that we will continue to follow up.
Adult received Pediatric dose of Havrix; Adult received Pediatric dose of Havrix; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult use of a child product in a 36-year-old male patient who received HAV (Havrix 720) (batch number 2X2EJ, expiry date 14-OCT-2024) for prophylaxis.   On 20-APR-2023, the patient received the 1st dose of Havrix 720. On 20-APR-2023, an unknown time after receiving Havrix 720, the patient experienced adult use of a child product (Verbatim: Adult received Pediatric dose of Havrix) and underdose (Verbatim: Adult received Pediatric dose of Havrix). The outcome of the adult use of a child product and underdose were unknown.   Additional Information: GSK Receipt Date: 16-APR-2023 The reporter was a medical assistant. The reporter reported that the adult patient received pediatric dose of Havrix vaccine. The reporter did consent to follow up. The adult patient was administered a pediatric dose of Havrix, which led to underdose and adult use of a child product. This case had been linked with US2023058970 by same reporter for different patient.; Sender's Comments:  US-GSK-US2023058970:Same reporter
diagnosed with rotavirus; acutely dehydrated; significant weight loss; This spontaneous report was received from a social worker (registered nurse) concerning to a 3 months old male patient. The patient's medical history, concurrent conditions and concomitant therapies were not provided. He had not known drug allergies.   On 24-JUN-2021, the patient was vaccinated with the first dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) 2 milliliter, administered orally (frequency, lot# and expiration date were not provided) for prevention of rotavirus gastroenteritis.   On 19-JUL-2021, the patient was diagnosed with rotavirus through blood works and a stool sample. He arrived at the hospital acutely dehydrated and had significant weight loss. The health care professional (HCP) admitted the patient into the hospital to receive support with fluids and a partial immune evaluation. At the time of the report, the patient was recovering from the events.   The causal relationship between the event and rotavirus vaccine, live, oral, pentavalent (ROTATEQ) was not provided.
This spontaneous report was received from a medical assistant referring to a 11 year old patient. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided. On 05-JUN-2017, the patient was vaccinated with an improperly stored dose of GARDASIL 9 with lot # N002720 and expiration date 12-MAY-2019 (dose and route of administration were not reported) for prophylaxis. There was no adverse effect or product quality complaint reported. No excursion details had been determined at the time of the report. There was a data logger involved. This is one of several reports received from the same reporter. Follow up information was received on 18-SEP-2017 from the medical assistant, concerning GARDASIL 9 with lot # M036059. On 11-MAY-2017 at 12:24, the time in the range 32°Fahrenheit (°F) to 35°F (0°C to 1°C) was 1 hour at 34.9°F, number of cycles 1. On the same day at 21:24, the time in the range 32°F to 35°F (0°C to 1°C) was 1 hour at 34.9°F, number of cycles 8. On 12-MAY-2017 at 03:24, the time in the range 32°F to 35°F (0°C to 1°C) was 1 hour at 34.9°F, number of cycles 5. On 13-MAY-2017 at 05:24, the time in the range 32°F to 35°F (0°C to 1°C) was 1 hour at 34.9°F, number of cycles 26. On 14-MAY-2017, the time in the range 32°F to 35°F (0°C to 1°C) was 2 hours from 16:24 to 18:24, number of cycles 21. On the same day at 20:24, the time in the range 32°F to 35°F (0°C to 1°C) was 1 hour at 34.9°F, number of cycles 1. On 15-MAY-2017, the time in the range 32°F to 35°F (0°C to 1°C) was 3 hours from 01:24 to 04:24, number of cycles 4. On the same day at 12:24, the time in the range 32°F to 35°F (0°C to 1°C) was 1 hour at 34.9°F, number of cycles 7. It has been determined that case # 1710USA009213 was created with the wrong Aware date as 02-OCT-2017 which is previous of the correct Aware date 18-SEP-2017. Therefore, case # 1710USA009213 is being deleted from our files and the case is consolidated into case # 1711USA003923 with the correct Aware Date 18-SEP-2017. Sender's Comments: US-009507513-1708USA011654.
Patient received vaccine in afternoon on 4/09/2021 in right deltoid. After leaving facility, within a couple hours later, patient reports feeling nauseated. Took Tylenol/Ibuprofen combo; unsure of Mg. Laid down for brief nap. Went to dinner following this. Patient reports feeling nauseated/light headed before her meal; after eating, patient reports feeling sick and vomited food back up. Patient then went home and began to experience hot/cold chills; attempted to resolve with hot bath. Patient went to bed and continued to feel uncomfortable on morning of 4/10/2021. Patient has reported drinking water throughout  AM and had developed a headache and continued to have hot/cold chills and body aches. Patient also unable to keep today?s lunch meal down; expelled via emesis today.
Systemic: Hypotension-Mild, Systemic: Vomiting-Medium, Additional Details: Patient received vaccination within 10 minutes, she felt lightheaded and fell to the ground. She did not fiant, but did vomit.
Malaise. Facial flushing/bosy flushing. Body aches. Feeling hot. Has goosebumps.
My adverse event started on 12/2022. I had digestive issue along with lower abdominal pain. They referred me to a Rheumatologist which I am waiting on blood work result at the moment. I will be going for the results on 04/12/2023. They also referred me to a Gastroenterologist which I will be going to on 04/25/2023. As of now the doctors are trying to rule out the cause of the pain I am having which is why they haven't prescribed me any medication yet. It is an ongoing issue I am having.
Patient developed swelling of her right arm, a knot under her skin, redness, body aches, headache and nausea.
pt recv vax; 2 days later, upper arm hot to touch, swollen & tender;
LEFT ANTERIOR THIGH NOTED 49 CM SMALL PUNCTURE, RED, SWELLING, AND BLISTERS.
Patient seen in our office on 9/19/2017 at 2:15 pm for a routine child health examination and weight check. Patient's 4 month vaccines given, as listed above. On 9/20/2017, patient was found infant unresponsive by parents. EMS called and arrived to find parents performing CPR. Patient transferred via EMS to ED. CPR unsuccessful. Time of death called at 7:34am in the ED.
acute decompensated heart failure new left ventricular dysfunction (EF 35-40%) acute kidney injury
pain at the injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (pain at the injection site) in a 68-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 010M21A and 010M20A) for COVID-19 vaccination.     The patient's past medical history included Arthritis since an unknown date. Concomitant products included BUDESONIDE, FORMOTEROL FUMARATE (SYMBICORT) and LORAZEPAM for an unknown indication.   On 02-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (pain at the injection site). At the time of the report, VACCINATION SITE PAIN (pain at the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No treatment information was provided.
They have been administering the vaccine after expiration date/30-day use by date expired vaccine was administered to several patients; They have been administering the vaccine after expiration date/30-day use by date expired vaccine was administered to several patients; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (They have been administering the vaccine after expiration date/30-day use by date expired vaccine was administered to several patients) and PRODUCT STORAGE ERROR (They have been administering the vaccine after expiration date/30-day use by date expired vaccine was administered to several patients) in a  patient of an unknown age and gender who received mRNA-1273 (Spikevax) (batch no. 027L21A) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Mar-2022, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 04-Mar-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (They have been administering the vaccine after expiration date/30-day use by date expired vaccine was administered to several patients). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (They have been administering the vaccine after expiration date/30-day use by date expired vaccine was administered to several patients). At the time of the report, EXPIRED PRODUCT ADMINISTERED (They have been administering the vaccine after expiration date/30-day use by date expired vaccine was administered to several patients) and PRODUCT STORAGE ERROR (They have been administering the vaccine after expiration date/30-day use by date expired vaccine was administered to several patients) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   Date the vial was initially stored in the refrigerator was on 28Jan2022.  No concomitant medication were reported.  No treatment medication were reported.
Patient is seen in Occ. Health for adverse reation to her Varicella vaccine. She has a red area 4" round that is warm and itchy.
Systemic: Dizziness / Lightheadness-Medium, Systemic: Fainting / Unresponsive-Medium, Additional Details: Patient felt dizzy and passed out shortly after vaccine administration. Patient had not had anything to eat or drink all day and has passed out before after blood draws. Patient recieved gatorade and a granola bar in the store and recovered within 30 min and left store with a friend.
Pt recvd vax 27Sep93; mom noticed morning of 28SEP93, hives all over pt; DPH given;
Could not inhale air and only could exhale through mouth and lasted around 45 seconds to 1 minute. She slowly was able to inhale and increased a little over 1 minute before full breathes were obtained. Total time course approximately 2 minutes.
Within 1 minute of receiving vaccination, patient fainted - slumped in chair, clammy, and pale.  Unresponsive to verbal stimuli.  Eyes rolled back with some jerkiness in extremities.  Resolved in about 1 minute.  No respiratory distress.  Became responsive to verbal stimuli and was alert and oriented.  Drank one bottle of orange juice, and after 10 minutes of sitting, able to walk back to monitor area without issue.  Observed another 20 minutes.
fever of 101.4, chills, aches and pain, foggy feeling, very painful arm, headache and scratchy throat
body aches; Tight shoulder and upper back and neck; Numbness on left side of face.; Bone and body aches; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 25Apr2021 at 10:15 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. Medical history included penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient did not receive any medication within two weeks of COVID-19 vaccine. On 26Apr2021, the patient experienced bone and body aches, tight shoulder and upper back and neck, numbness on left side of face. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events bone and body aches, tight shoulder and upper back and neck, numbness on left side of face was not recovered.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Like clockwork, within one weeks time to the hour, developed a rash at site of injection. Looking like topical contact dermatitis; red, itchy, burning, and raised. The rash has grown over the course of a couple of days. Taking an antihistamine which is keeping it at bay.
I didn't have any symptoms or signs. I took my blood pressure in the house hold and found it to be high. I took it a number of different times and it remained high. I visited a PA and was put on losartan 50 mg. I first took a half tablet and I don't recall the exact way I tapered up. But I take 50mg once a day now. When I rechecked with my PCP, the medication initially was not enough so I was raised to 50mg. I rechecked again with my PCP and it was in the range we wanted so that's my current outcome.
Foster parent reports child had a febrile seizure and was taken to emergency room by ambulance on 6/27/06.  Reports temperature was 104 degrees at hospital.
Patient received injection of DECAVE in the left deltoid on 8-22-08.  Patient called 8-25-08 and said she had a reaction to the tetanus shot, her arm got real sore, it got red and swollen, the size 1/2 dollar.  She also had a slight fever, headache and diarrhea.